FAD “Trattamento dei fattori di rischio cardiovascolare” Share Post navigation The impact of empagliflozin on obstructive sleep apnea, cardiovascular, and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trialEffects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial